Latest Headlines

  1. Icosagen Acquires The Carterra LSA Instrument To Significantly Enhance Its Antibody Screening Capabilities In The Discovery And Development Of New Therapeutic And Diagnostic Antibodies 3/20/2023

    Icosagen Group, an established research-driven organization providing services for the discovery and production of mammalian cell-derived biopharmaceuticals, today announced that it has acquired the LSA platform from Carterra, a leading provider of high-throughput antibody screening and characterization solutions.

  2. Synthego Introduces CRISPR Discovery Partners To Streamline CRISPR-Driven Drug Discovery Research 3/16/2023

    Synthego Corp., a leading genome engineering solutions provider, announced today the launch of its service partner ecosystem, CRISPR Discovery Partners, designed to accelerate drug discovery by providing a seamless research workflow from CRISPR editing to phenotypic data and downstream services.

  3. ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces A Multi-Target AI-Driven Antibody Discovery Collaboration With Libera Bio 3/15/2023

    Immunoprecise Antibodies Ltd. (“Immunoprecise” or “IPA” or the “Company”), an AI-driven biotherapeutic research and technology company, today announced that Talem Therapeutics LLC, an independently operating subsidiary of IPA, and Libera Bio S.L., have signed a collaboration agreement to jointly address intracellular targets.

  4. Aitia And UCB Announce Strategic Drug Discovery Collaboration In Huntington's Disease 3/15/2023

    UCB, a global biopharmaceutical company, and Aitia, the leader in the application of Causal AI and "Digital Twins" to discover and develop new drugs, today announced an early drug discovery collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntington's disease.

  5. Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme For Psychedelic-Inspired Drug Discovery 3/14/2023

    Enveric Biosciences a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today new research detailing the first-ever isolation of a novel indolethylamine N-methyltransferase from cane toad (Rhinella marina) and the successful development of a bioproduction platform for the isolation and pharmacological screening of novel indolethylamines.

  6. Ellipses Pharma: EP0042 Receives Orphan Drug Designation From The US Food And Drug Administration 3/14/2023

    Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an innovative drug development model, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to EP0042, a dual FLT-3 and Aurora kinase inhibitor, for the treatment of acute myeloid leukaemia (AML).

  7. Mabwell Launched First In Human Clinical Trial Of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011 3/14/2023

    Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, launched first in human clinical trial of its iron homeostasis regulating macromolecular drug 9MW3011.

  8. Scientists Reveal A Potential New Approach To Treating Liver Cancer 3/13/2023

    Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead to the development of a new class of anticancer drugs.

  9. New Research Collaboration Between Emory And Pfizer Aims To Advance The Discovery Of Antiviral Agents For COVID-19 3/13/2023

    As COVID-19 continues to evolve and impact the lives of people around the world, the need for additional effective treatment options continues to be at the forefront of global efforts to combat the disease.

  10. Acadia Pharmaceuticals Announces U.S. FDA Approval Of DAYBUE (trofinetide) For The Treatment Of Rett Syndrome In Adult And Pediatric Patients Two Years Of Age And Older 3/10/2023

    Acadia Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. DAYBUE is the first and only drug approved for the treatment of Rett syndrome.